Doxazosin Mesylate

CAS 77883-43-3 11 current records 8 historicalSmall Molecule

Who holds supplier records for Doxazosin Mesylate? 11 organisations hold a current record for Doxazosin Mesylate: an active US FDA Type II Drug Master File or a CEP. A further 8 organisations have only historical (inactive) DMF filings. 9 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (6), Germany (3) and Slovakia (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Doxazosin Mesylate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/doxazosin-mesylate

Reading the evidence

  • 11 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    6 of the 10 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 10 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

Current records (11)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Doxazosin Mesylate. Country is the organisation's recorded country, not necessarily the manufacturing site.

India6Germany3Slovakia1Country not recorded for 1
Need Doxazosin Mesylate sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (9)

Certificates of Suitability on the EDQM register for Doxazosin Mesylate, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 13 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
NOSCH LABS PRIVATE LIMITED HyderabadIN
CEP 2023-154 - Rev 01
Doxazosin mesilate
Aug 2026—
MIDAS PHARMA GMBH Ingelheim am RheinDE
CEP 2024-112 - Rev 01
Doxazosin mesilate, Process 2
Jul 2026Inspected Apr 2026
Germany
NIFTY LABS PRIVATE LIMITED HyderabadIN
CEP 2022-257 - Rev 01
Doxazosin mesilate
Sept 2025—
CHEMISCHE FABRIK BERG GMBH Bitterfeld-WolfenDE
CEP 2024-489 - Rev 00
Doxazosin mesilate, Form-II
Jan 2025Inspected May 2024
Germany
DR. REDDY'S LABORATORIES LIMITED HyderabadIN
CEP 2008-164 - Rev 06
Doxazosin mesilate
Jan 2025—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2006-289 - Rev 04
Doxazosin mesilate
Aug 2024—
COHANCE LIFESCIENCES LIMITED HyderabadIN
CEP 2010-312 - Rev 03
Doxazosin mesilate
Oct 2023—
EXCELLA GMBH & CO. KG FeuchtDE
R1-CEP 2008-328 - Rev 02
Doxazosin mesilate
Jun 2021—
SANECA PHARMACEUTICALS A.S. HlohovecSK
R1-CEP 2011-097 - Rev 02
Doxazosin mesilate
Dec 2020—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (8)

Organisations whose Type II DMFs for Doxazosin Mesylate are no longer active. These show a past filing, not current supply.

Show all 8 historical records
  • STANDARD CHEM AND PHARM CO LTD
    Inactive DMF 20770 · filed Aug 2007
  • CHONGQING BIOCARE PHARMACEUTICAL LTD
    Inactive DMF 20664 · filed Jun 2007
  • India · Inactive DMF 15240 · filed Jan 2001
  • Spain · Inactive DMF 14366 · filed Aug 1999
  • PHARMACEUTICAL FINE CHEMICALS PFC BAHAMAS LTD
    Inactive DMF 14281 · filed Jul 1999
  • Switzerland · Inactive DMF 14173 · filed Jun 1999
  • BASF PHARMACHEMIKALIEN GMBH CO KG
    Inactive DMF 13807 · filed Oct 1998
  • India · Inactive DMF 12784 · filed Dec 1997

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Doxazosin Mesylate is an alpha-1 adrenergic blocker used primarily to treat hypertension and benign prostatic hyperplasia. It relaxes blood vessels and muscles in the prostate and bladder neck, making it easier to urinate and lower blood pressure.

Chemical identity

IUPAC name
[4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(2,3-dihydro-1,4-benzodioxin-3-yl)methanone;methanesulfonic acid
Canonical SMILES
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC.CS(=O)(=O)O
InChIKey
VJECBOKJABCYMF-UHFFFAOYSA-N
Synonyms
Cardura API, alfadil, cardura, doxazosin (as mesilate), doxazosin mesilate, doxazosin methanesulfonate, nsc-759284, uk-33,274-27, uk-33274-27

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
alpha-Adrenergic Blocker
Mechanism of action
Adrenergic alpha-Antagonists

Therapeutic areas

CardiovascularUrology

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Doxazosin Mesylate?

11 organisations hold an active US FDA Type II Drug Master File or a CEP for Doxazosin Mesylate: APITORIA PHARMA PRIVATE LTD (India), COHANCE LIFESCIENCES LTD (India), Dr. Reddy's Laboratories Ltd. (India), EXCELLA GMBH AND CO KG (Germany), Apotex Pharmachem India Pvt. Ltd. (India), Unichem Laboratories Ltd. (India), CHEMISCHE FABRIK BERG GMBH (Germany) and MIDAS PHARMA GMBH (Germany), and 3 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Doxazosin Mesylate Drug Master Files are active?

APITORIA PHARMA PRIVATE LTD (DMF 19959), COHANCE LIFESCIENCES LTD (DMF 22941), Dr. Reddy's Laboratories Ltd. (DMF 12750), EXCELLA GMBH AND CO KG (DMF 12634), Apotex Pharmachem India Pvt. Ltd. (DMF 13039) and Unichem Laboratories Ltd. (DMF 32375). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Doxazosin Mesylate records mean?

8 organisations have only inactive Type II DMFs for Doxazosin Mesylate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Doxazosin Mesylate have a European Certificate of Suitability?

Yes. 9 organisations hold a valid CEP for Doxazosin Mesylate on the EDQM register, including NOSCH LABS PRIVATE LIMITED Hyderabad (IN), MIDAS PHARMA GMBH Ingelheim am Rhein (DE), NIFTY LABS PRIVATE LIMITED Hyderabad (IN), CHEMISCHE FABRIK BERG GMBH Bitterfeld-Wolfen (DE), DR. REDDY'S LABORATORIES LIMITED Hyderabad (IN) and APITORIA PHARMA PRIVATE LIMITED Hyderabad (IN) and 3 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

How do I qualify a Doxazosin Mesylate supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Doxazosin Mesylate?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.